CVS Pharmacy Finalizes Nationwide Acquisition of Rite Aid and Bartell Drugs Assets, Expanding Access to Care Across the U.S. CVS Pharmacy, a subsidiary of CVS Health, today announced the successful completion of its acquisition of select Rite Aid assets across…
WHO Warns of Global Neurological Health Crisis: Over 11 Million Deaths Annually Demand Urgent Action The World Health Organization (WHO) has issued a stark warning about the growing global burden of neurological disorders, revealing that less than one in three…
GSK’s Shingrix Receives Approval in China to Protect Immunocompromised Adults Against Shingles GSK plc (LSE/NYSE: GSK) today announced that the China National Medical Products Administration (NMPA) has granted approval for Shingrix—GSK’s Recombinant Zoster Vaccine (RZV)—for the prevention of shingles (herpes…
Regeneron Presents Latest DB-OTO Data Showing Dramatic and Sustained Hearing and Speech Improvements in Children with Profound Genetic Hearing Loss Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data for its investigational gene therapy DB-OTO for profound genetic hearing loss…
Data includes seven-year results from monarchE trial and updates on multiple investigational cancer therapies. Eli Lilly and Company (NYSE: LLY) announced today that it will present new data from a broad spectrum of its oncology portfolio at the upcoming European…
Oticara Reports Positive Phase 2 Results for Novel Nasal-Mucosa-Optimized Steroid Cream in Hard-to-Treat Post-Surgical Chronic Rhinosinusitis Oticara, a clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic rhinosinusitis (CRS), has announced encouraging outcomes from its Phase 2 OT-007B clinical…
IDT and Hamilton Partner to Automate NGS Workflows, Accelerating Biomarker and Genomic Discovery Integrated DNA Technologies (IDT), a global leader in genomics solutions, has announced a new strategic partnership with precision laboratory automation pioneer Hamilton (Hamilton Company and Hamilton Bonaduz…
Pulse Biosciences Unveils Promising First-in-Human Feasibility Data for the nPulse™ Cardiac Surgical System at EACTS 2025 Pulse Biosciences, Inc. (Nasdaq: PLSE), a clinical-stage medical technology company pioneering the use of its novel nPulse™ technology based on Nanosecond Pulsed Field Ablation™…
Prilenia and Ferrer Highlight Compelling New Evidence of Pridopidine’s Disease-Modifying Potential in Huntington’s Disease at the 2025 HSG Congress Prilenia Therapeutics B.V. and Ferrer have jointly announced the presentation of five new scientific posters at the 2025 Huntington Study Group…
Novo Nordisk to Acquire Akero Therapeutics to Strengthen MASH Pipeline with Phase 3 FGF21 Analogue Efruxifermin Novo Nordisk, a global healthcare leader in diabetes and obesity treatments, has announced a definitive agreement to acquire Akero Therapeutics, Inc., a publicly traded,…
Eikonizo Therapeutics Highlights Breakthrough Preclinical Findings Demonstrating the Disease-Modifying Potential of Selective HDAC6 Inhibitors in ALS and FTD Eikonizo Therapeutics, a biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative and cardiorenal diseases, has announced the advance online publication of…
Aarvik Therapeutics Secures Strategic Investment from Laurus Labs in Series Seed 2 Financing Round Aarvik Therapeutics, a pioneering biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for cancer therapy, today announced a strategic investment by Laurus Labs, India, as…